5-hydroxytryptamine receptor 7 activity modulators and their method of use
US-10676464-B2 · Jun 9, 2020 · US
5-hydroxytryptamine receptor 7 activity modulators and their method of use
US11897870B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11897870-B2 |
| Application number | US-202016861075-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2020 |
| Priority date | Mar 11, 2013 |
| Publication date | Feb 13, 2024 |
| Grant date | Feb 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound according to the following formula, or a pharmaceutically acceptable salt thereof, wherein n is 2; each of R 1a and R 1b is C 1-6 linear alkyl; and R 3 is optionally substituted heteroaryl. 2. The compound of claim 1 , wherein each of R 1a and R 1b is ethyl. 3. The compound of claim 1 , wherein R 3 is optionally substituted pyridyl. 4. The compound of claim 3 , wherein R 3 is unsubstituted pyridyl. 5. The compound of claim 3 , wherein R 3 is substituted pyridyl. 6. The compound of claim 1 , wherein R 3 is optionally substituted 2-pyridyl, optionally substituted 3-pyridyl, or optionally substituted 4-pyridyl. 7. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers.
Assignees
Inventors
Classifications
- C07D405/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
in position 2, the oxygen atom being in its keto or unsubstituted enol form · CPC title
spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11897870B2 cover?
- Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
- Who is the assignee on this patent?
- Univ Temple, Temple Univ Of The Commonwealth System Higher Education
- What technology area does this patent fall under?
- Primary CPC classification C07D405/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).